Can P1NP Levels Influence Management Planning for Patients With a Fragility Hip Fracture Receiving Anti-resorptive Medications?

In this selected cohort, measuring pre-operative P1NP levels supported patient-centred multidisciplinary (MDT) bone health planning. Clinicians considered P1NP alongside DXA findings and the broader clinical context when documenting MDT post-fracture bone health plans, with management changes commonly recorded among patients receiving long-term therapy (>5 years). Notably, in this long-term treated group, suppressed P1NP commonly coincided with documented decisions to stop or adjust therapy. Given the retrospective design, small sample size, lack of a comparator group, and absence of outcome data, these findings provide real-world insight into current practice and may support development of a more standardised approach to incorporating P1NP into post-fracture bone health pathways.